Orchestra BioMed Holdings (Orchestra BioMed Holdings) Accounts Receivable : $0.07 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Orchestra BioMed Holdings Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Orchestra BioMed Holdings's accounts receivables for the quarter that ended in Mar. 2024 was $0.07 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Orchestra BioMed Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 9.86.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Orchestra BioMed Holdings's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $1.39.

Orchestra BioMed Holdings Accounts Receivable Historical Data

The historical data trend for Orchestra BioMed Holdings's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchestra BioMed Holdings Accounts Receivable Chart

Orchestra BioMed Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

0.17

0.12

0.10

Orchestra BioMed Holdings Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial							0.08	0.17	0.09	0.10	0.07

Orchestra BioMed Holdings Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Orchestra BioMed Holdings Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Orchestra BioMed Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.067	/	0.62	*	91
=	9.86

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Orchestra BioMed Holdings's accounts receivable are only considered to be worth 75% of book value:

Orchestra BioMed Holdings's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(75.038	+	0.75 * 0.067	+	0.5 * 0.115	-	25.44
-	0	-	0)	/	35.785
=	1.39

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Orchestra BioMed Holdings Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Orchestra BioMed Holdings's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 Union Square Drive,, New Hope, PA, USA, 18938

Website

https://www.orchestrabiomed.com

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Executives

George Papandreou	officer: See Remarks	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Eric S Fain	director	ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
David P Hochman	director, officer: See Remarks	15 WESTON HILL RD., RIVERSIDE CT 06878
Joshua Aiello	officer: Principal Accounting Officer	150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Yuval Mika	officer: See Remarks	150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Pamela Ann Connealy	director	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Darren Sherman	director, officer: See Remarks	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Rose Eric A Md	director	161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Andrew Lawrence Taylor	officer: Chief Financial Officer	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
William Reed Little	officer: See Remarks	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Plc Medtronic	10 percent owner	20 ON HATCH, LOWER HATCH STREET, DUBLIN L2 2
Michael Kaswan	officer: Chief Financial Officer	KBL HEALTHCARE ACQUISITION CORP II, 645 MADISON AVENUE, NEW YORK NY 10022
Geoffrey Wade Smith	director	6740 SHADY OAK ROAD, EDEN PRAIRIE MN 55344
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014